GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Supernus Pharmaceuticals Inc (LTS:0LB2) » Definitions » ROE % Adjusted to Book Value

Supernus Pharmaceuticals (LTS:0LB2) ROE % Adjusted to Book Value : 0.03% (As of Mar. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Supernus Pharmaceuticals ROE % Adjusted to Book Value?

Supernus Pharmaceuticals's ROE % for the quarter that ended in Mar. 2024 was 0.05%. Supernus Pharmaceuticals's PB Ratio for the quarter that ended in Mar. 2024 was 1.98. Supernus Pharmaceuticals's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2024 was 0.03%.


Supernus Pharmaceuticals ROE % Adjusted to Book Value Historical Data

The historical data trend for Supernus Pharmaceuticals's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Supernus Pharmaceuticals ROE % Adjusted to Book Value Chart

Supernus Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROE % Adjusted to Book Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only 10.79 9.86 3.09 3.30 0.09

Supernus Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.46 -0.20 -4.01 0.29 0.03

Competitive Comparison of Supernus Pharmaceuticals's ROE % Adjusted to Book Value

For the Drug Manufacturers - Specialty & Generic subindustry, Supernus Pharmaceuticals's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Supernus Pharmaceuticals's ROE % Adjusted to Book Value Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Supernus Pharmaceuticals's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Supernus Pharmaceuticals's ROE % Adjusted to Book Value falls into.



Supernus Pharmaceuticals ROE % Adjusted to Book Value Calculation

Supernus Pharmaceuticals's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2023 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=0.15% / 1.75
=0.09%

Supernus Pharmaceuticals's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2024 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=0.05% / 1.98
=0.03%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Supernus Pharmaceuticals ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Supernus Pharmaceuticals's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Supernus Pharmaceuticals (LTS:0LB2) Business Description

Traded in Other Exchanges
Address
9715 Key West Avenue, Rockville, MD, USA, 20850
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. The Company's diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.

Supernus Pharmaceuticals (LTS:0LB2) Headlines

No Headlines